DATA GRAPHICS | Data Byte
Prostate cancer data lead to a nearly 70% stock bump; dermatitis data sink Q32 shares
By BioCentury Staff
December 12, 2024 12:07 AM UTC
Amid a busy period for clinical readouts, Candel led gainers on the market among biopharmas posting data since the stock market closed on Tuesday.
Shares in President and CEO Paul Peter Tak’s biotech, Candel Therapeutics Inc. (NASDAQ:CADL), rose $3.14 to $7.75 for a 68% gain and a closing market cap north of $250 million on the back of positive top-line data for CAN-2409 in intermediate-to-high risk localized prostate cancer. Candel plans to speak with FDA about the regulatory path forward…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654448/candel-leads-biotech-gainers-amid-wave-of-data-readouts